EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Knowledge Base of Designs and Statistical Methods for Adaptive Clinical Dose‐Finding Trials

Rob Kessels iD, Yongxi Long iD, Rene Spijker, Ewoud Schuit, Marieke Hollestelle iD, Chris van Lieshout, Neeltje Steeghs, Sjoerd G Elias, Peter M van de Ven

Pharmaceutical Statistics · 2026-07 · 25 (4)

DOI: 10.1002/pst.70074 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutical Statistics, online erschienen am 19.05.2026. Verfasst von Rob Kessels und 8 weiteren Autor:innen. Beteiligte Einrichtung: Julius Center for Health Sciences and Primary Care, Department of Data Science and Biostatistics, University Medical Center Utrecht, Utrecht Universi…. Hauptthemen laut MEDLINE: Research Design, Antineoplastic Agents, Adaptive Clinical Trials as Topic. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch National Growth Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adaptive clinical dose‐finding trials aim to identify an optimal drug dose for use in subsequent phase II and III trials. In adaptive dose‐finding trials, dose levels for newly included patients are informed by outcomes of patients that received the drug earlier in the trial. The body of methodological research on adaptive dose‐finding trials is extensive, but a clear overview is lacking. The goal of this paper is to provide a knowledge base of designs and statistical methods for adaptive clinical dose‐finding trials by means of a literature review. We identified 315 adaptive dose‐finding trial methodology articles of which the majority was inspired by oncology. Recent methods focused on identification of an optimal dose considering both toxicity and efficacy endpoints, and addressing challenges related to subgroup‐specific dose‐finding, dose‐finding for combination therapies, and incorporation of delayed outcomes in dose‐finding. These developments are driven by the emergence of newer classes of cancer drugs, such as targeted therapies and immunotherapies, and by initiatives like Project Optimus. Most articles focused on model‐based designs, like the Continual Reassessment Method (CRM), but recent years have seen a strong increase in model‐assisted or interval‐based designs, including Toxicity Probability Interval (TPI) and Bayesian Optimal Interval (BOIN) designs and expansions thereof. Considering the increasing availability and large variety of adaptive dose‐finding trial designs, it is challenging for researchers to find relevant designs tailored to their needs. Therefore, we provide an interactive map summarizing the classification of our results to facilitate the identification of relevant designs/methods, which we will update regularly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignAntineoplastic AgentsAdaptive Clinical Trials as TopicHumansDose-Response Relationship, DrugModels, StatisticalClinical Trials, Phase II as Topic

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Julius Center for Health Sciences and Primary Care, Department of Data Science and Biostatistics, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden University, Leiden, the Netherlands.
  • Cochrane Netherlands, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Julius Center for Health Sciences and Primary Care, Department of Epidemiology and Health Economics, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Julius Center for Health Sciences and Primary Care, Department of Global Public Health and Bioethics, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

ORCID-Profile: Rob Kessels, Yongxi Long, Marieke Hollestelle

Förderung

  • Dutch National Growth Fund

Zitieren

APA

Kessels, R., Long, Y., Spijker, R., Schuit, E., Hollestelle, M., van Lieshout, C., Steeghs, N., Elias, S. G., & van de Ven, P. M. (2026). A Knowledge Base of Designs and Statistical Methods for Adaptive Clinical Dose‐Finding Trials. Pharmaceutical Statistics, 25(4). https://doi.org/10.1002/pst.70074

Vancouver

Kessels R, Long Y, Spijker R, Schuit E, Hollestelle M, van Lieshout C, et al. A Knowledge Base of Designs and Statistical Methods for Adaptive Clinical Dose‐Finding Trials. Pharmaceutical Statistics. 2026;25(4). doi:10.1002/pst.70074

BibTeX
@article{Kessels2026,
  author = {Kessels, Rob and Long, Yongxi and Spijker, Rene and Schuit, Ewoud and Hollestelle, Marieke and van Lieshout, Chris and Steeghs, Neeltje and Elias, Sjoerd G and van de Ven, Peter M},
  title = {A Knowledge Base of Designs and Statistical Methods for Adaptive Clinical Dose‐Finding Trials},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  volume = {25},
  number = {4},
  doi = {10.1002/pst.70074}
}
Kostenlos starten →